The German Breast Group’s newsroom
Our newsroom provides you with the latest information about the German Breast Group. This section of the website also includes photographic material and information about our events. In addition, our Annual Scientific Reports, which provide an overview of our research activities, can be downloaded here.
-
18.05.2020 Locoregional recurrence risk after neoadjuvant chemotherapy
A pooled analysis of nine prospective neoadjuvant breast cancer trials that aimed to identify independent predictors of Locoregional recurrence risk after neoadjuvant chemotherapy has been published in European Journal of Cancer.
-
30.04.2020 A small hypoxia signature predicts response to neoadjuvant bevacizumab treatment
A translational research project aiming to identify predictive markers for response to bevacizumab treatment in HER2-negative breast cancer from GeparQuinto study has been published in Clinical Cancer Research.
-
02.04.2020 Study guidance or the COVID-19-Pandemic
Information in order to treat the patients in the clinical study in the best possible way and in accordance with the protocol.
-
24.03.2020 March 2020: Predefined surgical analysis of the randomized BrighTNess trial
We are pleased to inform you that the surgical results of the randomized BrighTNess trial have been published in JAMA Surgery.
-
28.02.2020 February 2020: Long-term follow-up results of the IBIS-II trial
We are delighted to inform you that the long-term follow-up results of the randomized IBIS-II trial have been published in Lancet.
-
01.02.2020 January 2020: A combination of trastuzumab with tailored dose-dense adjuvant chemotherapy reduces risk of relapse in HER2-positive breast cancer
Results of a protocol-predefined secondary analysis from PANTHER trial have been published in Cancer.
-
01.01.2020 December 2019: HLA class I evaluation in breast cancer patients from GeparTrio trial
A translational study evaluating the role of tumor immunogenicity in patients from GeparTrio trial has been published in Breast Cancer Research.
-
12.12.2019 SABCS 2019: Effects of capecitabine in neo-/adjuvant chemotherapy
A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. Presented as SABCS 2019.
-
06.12.2019 GBG presentations at SABCS
We are happy to present our contributions at the San Antonio Breast Cancer Symposium 2019.
-
29.11.2019 November 2019: Androgen receptor expression and response to chemotherapy
A translational study investigating androgen receptor expression in breast cancer patients receiving neoadjuvant chemotherapy from the TECHNO and PREPARE trials has been published in the British Journal of Cancer.
-
08.11.2019 October 2019: Toxicity analysis of neutropenic complications in adjuvant tailored dose-dense chemotherapy from the PANTHER study
Results of a secondary exploratory toxicity analysis investigating neutropenic complications in the phase III PANTHER trial of standard 3-weekly chemotherapy with FEC/D versus bi-weekly tailored dose-dense EC/D adjuvant chemotherapy in breast cancer have been published in the Acta Oncologica
-
21.10.2019 ESMO 2019 Congress: Merit Award
Jenny Furlanetto, MD honoured with the Merit Award to the ESMO 2019 Congress
-
27.09.2019 September 2019: Impact of post-mastectomy radiotherapy (RT) after neoadjuvant chemotherapy (NACT) on survival in breast cancer patients
Results of a retrospective pooled analysis from three randomized neoadjuvant GBG trials (GeparTrio, GeparQuattro and GeparQuinto) evaluating the impact of post-mastectomy RT (PMRT) after NACT on survival in breast cancer patients have been published in the Annals of Surgical Oncology.
-
17.09.2019 GBG research at ESMO 2019
Data of GBG research projects were presented at ESMO 2019, September 27th to October 1st in Barcelona.
-
12.09.2019 August 2019: Results of a pooled analysis from two randomized phase III trials [LEA GBG51 and Cancer and Leukemia Group (CALGB) 40503] evaluating the addition of bevacizumab to endocrine therapy (ET) as first-line treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC)
Data from two similar randomized phase III trials (LEA GBG51 and CALGB 40503) comparing the efficacy of standard ET versus experimental ET plus bevacizumab as first-line treatment for HR-positive MBC have been published in the European Journal of Cancer
-
10.09.2019 Save the date: AGO State of the Art Meeting 2020
The AGO State of the Art Meeting 2020 will take place 29th of February at the InterContinental Hotel, Wilhelm-Leuschner-Straße 43, 60329 Frankfurt. Please save the date!
-
10.09.2019 Save the date: GBG Annual Meeting 2020
The GBG Annual Meeting 2020 will take place 27.-28. February at the InterContinental Hotel, Wilhelm-Leuschner-Straße 43, 60329 Frankfurt.. Please save the date!
-
31.07.2019 July 2019: Fatal events occurring during study treatment: a pooled analysis of death cases within GBG led breast cancer trials
We are glad to inform you that the results of a pooled analysis evaluating fatal events during GBG led breast cancer trials have been published in the Breast Cancer
-
04.07.2019 June 2019: Clinical results and biomarker analysis of the randomised phase II GeparNuevo study
We are pleased to inform you that the results of the randomised phase II GeparNuevo (GBG 89) study that aimed to investigate the addition of durvalumab, a human monoclonal antibody targeting programmed cell death ligand-1 (PD-L1) to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer (TNBC) has been published in the Annals of Oncology.
-
03.06.2019 May 2019: Long-term outcomes of the GeparSepto study
The long-term follow-up data of the phase III GeparSepto (GBG 69) study that aimed to compare weekly nab-paclitaxel with weekly sb-paclitaxel followed by epirubicin plus cyclophosphamide (EC) as neoadjuvant treatment in patients with primary breast cancer has been published in the Journal of Clinical Oncology.
